Monitoring
The first year following diagnosis, patients should be reviewed every 3 to 4 months, with re-staging CT scan of chest, abdomen, and pelvis performed every 4 months, plus blood tests including chromogranin A and urinary 5-hydroxyindoleacetic acid (5-HIAA).[71] If symptoms progress or deteriorate, patients may also undergo further Octreoscan®. From the second year onwards, if tumour appears to be stable, then 6-monthly re-staging scans, plus blood tests, and urinary 5-HIAA can be performed. Octreoscan® can be performed annually.[71]
Use of this content is subject to our disclaimer